Navigation Links
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Date:6/1/2009

sident and Chief Medical Officer at Cephalon.

About NUVIGIL

NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work sleep disorder, also known as shift work disorder (SWD) and narcolepsy. The NUVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson Syndrome, that has been reported in adults and children taking modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (greater than 5 percent) were headache, nausea, dizziness, and insomnia. Full prescribing information for NUVIGIL is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, a
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
2. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
3. Cephalon Acquires Controlling Interest in Arana Therapeutics
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
6. Cephalon Quarterly Conference Call Invitation
7. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
8. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
9. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... led by the Wellcome Trust Sanger Institute announce the ... cancers are caused by mutations in the DNA of ... The studies, of a malignant melanoma and a lung ... mutations in the genomes of two cancers. , Lung ... almost all are associated with smoking. The number of ...
(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
(Date:12/16/2009)... MassBio promote Massachusetts companies through annual marketing campaign , ... ... -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , ,Genetown is sponsored by MassBio and ... industries. The campaign places each entity’s brand on an ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Thriving Bioscience Region Leaves Its Mark 2
... neurological disorder in which misfiring electrical impulses in the ... epilepsy, and more than a million are female. //Pregnant ... that their children will have problems ranging from congenital ... to growing evidence that many commonly prescribed anti-epileptic drugs ...
... treatments may further increase the risk of breast and ... //Researchers offer new evidence that herbs such as red ... - as well as saw palmetto and rhodiola rosea ... could increase the risk of estrogen-related cancers. ...
... for long hours are more likely to be agitated.The ... and the New York State Psychiatric Institute. His team tracked ... found that those who had watched one or more hours ... into fights or behave aggressively towards other people later in ...
... According to a study, siblings of people with Alzheimer's ... of dementia.// More than half of patients with Alzheimer's ... This is an especially serious form of the condition, ... earlier need for institutional care. ,Researchers at ...
... Researchers say they've taken a major step toward cloning ... transplanted into humans. Such organs would save the lives ... transplants because of the shortage of human organs.// ... Dolly, scientists say they produced four piglets without one ...
... anxiety during pregnancy can increase a mother's risk of ... who were very anxious// in the last three months ... ,Lead researcher Professor Vivette Glover, of Imperial College, ... had extreme anxiety, and were frequently feeling scared.According ...
Other Medicine News:Health News: Pig cloning for organs, 2
(Date:12/16/2009)... (Nasdaq: ARAY ), a global leader in the ... chief executive officer, Euan S. Thomson, Ph.D., is scheduled ... Conference in San Francisco on Wednesday, January 13, 2010 ... live webcast of each presentation will be available online ... site at http://www.accuray.com . The webcast replay ...
(Date:12/16/2009)... -- DATATRAK International, Inc. (OTCQX: DATA), a ... eClinical solutions for the clinical trials industry, ... 9.0 eClinical Software. This release advances ... service delivery and introduces two new mechanisms ... DATATRAK Learning Center(TM) and the DATATRAK Learning ...
(Date:12/16/2009)... Dec. 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... had secured $1 million in 12% per annum short ... facility is an initial drawdown of $500,000, with accrued ... drawdown of $500,000 with accrued interest and principal repayable ... the Company becoming cashflow positive for any calendar month ...
Breaking Medicine Technology:Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 1Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 2Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 3Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 4Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 1Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 2Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 3AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 1AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 2AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 3AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 4AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 5AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 6AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 7
... -- for Lung Cancer Diagnosis and, Identification of Tumor Origin in Patients With Cancer ... ... Types With High Sensitivity and, Specificity and Could Revolutionize Diagnosis and Treatment ... Accuracy Exceeding 90% and ...
... Novel Approach to Blood ... Pressure ... innovator in the discovery and development of novel small,molecule therapeutics, ... showed statistically significant,blood pressure reductions in a Phase 2a study ...
Other Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
... Knee design includes several innovative ... porous coating option for stable ... unique bone preserving posterior stabilizing ... to maximize range of motion, ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
Medicine Products: